RxDoctor Payments Data

Laura Butterwick, MD

Internal Medicine · Southampton, PANPI 1184695363

Payments from drug & device makers

$13,003in general payments, 2019–2025

Across 815 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Amgen$936
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$932
  • Pfizer$687
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$12,90799%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,003 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$224,616
Medicare patients
497
Services billed
2,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$131,930
EliquisApixaban124$114,801
MounjaroTirzepatide73$81,647
JardianceEmpagliflozin37$42,151
FarxigaDapagliflozin Propanediol41$33,214
JanumetSitagliptin Phos/Metformin Hcl22$26,151
LinzessLinaclotide45$25,070
VraylarCariprazine Hcl16$22,398
MyrbetriqMirabegron38$22,079
ProliaDenosumab12$20,790
TrulicityDulaglutide15$15,537
BelsomraSuvorexant30$14,834
XareltoRivaroxaban11$12,134
Breo ElliptaFluticasone/Vilanterol30$12,121
Rosuvastatin Calcium500$11,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,059$131,930102 claims
PfizerEliquis, Paxlovid$687$119,072155 claims
Lilly USA, LLCMounjaro, Trulicity$530$97,18488 claims
AbbVieLinzess, Vraylar, Synthroid$2,385$53,614143 claims
Boehringer IngelheimJardiance, Spiriva Respimat$131$52,36057 claims
MerckJanumet, Belsomra$473$40,98552 claims
AstraZenecaFarxiga, Symbicort$1,115$37,12352 claims
Astellas Pharma US IncMyrbetriq$300$22,07938 claims
AmgenProlia$936$20,79012 claims
GSKBreo Ellipta, Anoro Ellipta$266$17,26041 claims
Johnson & JohnsonXarelto$231$12,13411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Southampton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →